Vitamin B status in patients with type 2 diabetes mellitus with and without incipient nephropathy

Diabetes Research and Clinical Practice

Volumn 107, Issue 1, 2015, Pages 157-165

  Nix, Wilfred A ^a   Zirwes, Rudolf ^b   Bangert, Volkhard ^b   Kaiser, Raimund Peter ^c   Schilling, Matthias ^d   Hostalek, Ulrike ^e   Obeid, Rima ^f  

^a Akademie für Ärztliche Fortbildung in Rheinland Pfalz ^*  (Germany)

^b Abteilung Innere Medizin Krankenhaus Maria Hilf   (Germany)

^c Private Practice   (Germany)

^d Private Practice   (Germany)

^e MERCK KGAA   (Germany)

^f AARHUS UNIVERSITY   (Denmark)

Author keywords

Microalbuminuria; Pyridoxal 5' phosphate; Type 2 diabetes; Vitamin B deficiency

Indexed keywords

C REACTIVE PROTEIN; CYANOCOBALAMIN; HOMOCYSTEINE; METHYLMALONIC ACID; PYRIDOXAL; PYRIDOXAL 5 PHOSPHATE; PYRIDOXAMINE; PYRIDOXAMINE PHOSPHATE; PYRIDOXIC ACID; PYRIDOXINE; THIAMINE; VASCULAR CELL ADHESION MOLECULE 1; BIOLOGICAL MARKERS; VITAMIN B 12; VITAMIN B 6;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; INFLAMMATION; KIDNEY FUNCTION; LIPID METABOLISM; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PYRIDOXINE DEFICIENCY; THIAMINE DEFICIENCY; URINE LEVEL; VITAMIN BLOOD LEVEL; AGED, 80 AND OVER; ALBUMINURIA; BLOOD; CASE-CONTROL STUDIES; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; MIDDLE AGED; VITAMIN B 12 DEFICIENCY; VITAMIN B 6 DEFICIENCY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINURIA; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PYRIDOXIC ACID; THIAMINE; VITAMIN B 12; VITAMIN B 12 DEFICIENCY; VITAMIN B 6; VITAMIN B 6 DEFICIENCY; YOUNG ADULT;

EID: 84922825541     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.09.058     Document Type: Article

References (50)

1. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414(6865):813-820.
2. Gilg J., Castledine C., Fogarty D. Chapter 1 UK RRT incidence in 2010: national and centre-specific analyses. Nephron Clin Pract 2012, 120(Suppl 1):c1-c27.
3. United States Renal Data System 2012 USRDS annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States 2012, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, Available at: 〈http://www.usrds.org/2012/slides/indiv/v2index.html〉 [last accessed on 25 Feb 2014].
4. Adler A.I., Stevens R.J., Manley S.E., Bilous R.W., Cull C.A., Holman R.R. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003, 63(1):225-232.
5. Keenan H.A., Costacou T., Sun J.K., Doria A., Cavellerano J., Coney J., et al. Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study. Diabetes Care 2007, 30(8):1995-1997.
6. Degenhardt T.P., Adlerson N.L., Arrington D.D., Beattie R.J., Basgen J.M., Steffes M.W., et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002, 61(3):939-950.
7. Nakamura S., Li H., Adijiang A., Pischetsrieder M., Niwa T. Pyridoxal phosphate prevents progression of diabetic nephropathy. Nephrol Dial Transplant 2007, 22(8):2165-2174.
8. Babaei-Jadidi R., Karachalias N., Ahmed N., Battah S., Thornalley P.J. Prevention of incipient diabetic nephropathy by high dose thiamine and benfotiamine. Diabetes 2003, 52(8):2110-2120.
9. Rabbani N., Alam S.S., Riaz S., Larkin J.R., Akhtar M.W., Shafi T., et al. High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomized, double-blind placebo-controlled pilot study. Diabetologia 2009, 52(2):208-212.
10. Polizzi F.C., Andican G., Çetin E., Civelek S., Yumuk V., Burçak G. Increased DNA-glycation in type 2 diabetic patients: the effect of thiamine and pyridoxine therapy. Exp Clin Endocrinol Diabetes 2012, 120(6):329-334.
11. Reddi A.S., Jyothirmayi G.N., DeAngelis B., Frank O., Baker H. Tissue concentrations of water-soluble vitamins in normal and diabetic rats. Int J Vitam Nutr Res 1993, 63(2):140-144.
12. Okada M., Shibuya M., Yamamoto E., Murakami Y. Effect of diabetes on vitamin B6 requirement in experimental animals. Diabetes Obes Metab 1999, 1(4):221-225.
13. Babaei-Jadidi R., Karachalias N., Kupich C., Ahmed N., Thornalley P.J. High-dose thiamine therapy counters dyslipidaemia in streptozotocin-induced diabetic rats. Diabetologia 2004, 47(12):2235-2246.
14. Thornalley P.J., Babaei-Jadidi R., Al Ali H., Rabbani N., Antonysunil A., Larkin J., et al. High prevalence of low plasma thiamine concentration in diabetes linked to marker of vascular disease. Diabetologia 2007, 50(10):2164-2170.
15. Pflipsen M., Oh R.C., Saguil A., Seehusen D.A., Seaquist D., Topolski R. The prevalence of Vitamin B(12) deficiency in patients with type 2 diabetes: a cross-sectional study. J Am Board Fam Med 2009, 22(5):528-534.
16. Satyanarayana A., Balakrishna N., Pitla S., Reddy P.Y., Mudili S., Lopamudra P., et al. Status of B-vitamins and homocysteine in diabetic retinopathy: association with vitamin-B12 deficiency and hyperhomocysteinemia. PLoS One 2011, 6(11):e26747.
17. Al-Atta O.S., Al-Daghri N.M., Alfadda A.A., Abd-Alrahman S.H., Sabico S. Blood thiamine and its phosphate esters as measured by high-performance liquid chromatography: levels and associations in diabetes mellitus patients with varying degrees of microalbuminuria. J Endocrinol Invest 2012, 35(11):951-956.
18. Obeid R., Jung J., Falk J., Herrmann W., Geisel J., Friesenhahn-Ochs B., et al. Serum vitamin B12 not reflecting vitamin B12 status in patients with type 2 diabetes. Biochimie 2013, 95(5):1056-1061.
19. Sander S., Hahn A., Stein J., Rehner G. Comparative studies on the high-performance liquid chromatographic determination of thiamine and its phosphate esters with chloroethylthiamine as an internal standard using pre- and post-column derivatization procedures. J Chromatogr 1991, 558:115-124.
20. Bisp M.R., Bor M.V., Heinsvig E.M., Kall M.A., Nexø E. Determination of vitamin B6 vitamers and pyridoxic acid in plasma: development and evaluation of a high-performance liquid chromatographic assay. Anal Biochem 2002, 305(1):82-89.
21. Adaikalakoteswari A., Rabbani N., Waspadji S., Tjokroprawiro A., Kariadi S.H., Adam J.M., et al. Disturbance of B-vitamin status in people with type 2 diabetes in Indonesia-link to renal status, glycemic control and vascular inflammation. Diabetes Res Clin Pract 2012, 95(3):415-424.
22. Leklem J.E. Vitamin B-6: a status report. J Nutr 1990, 120:1503-1507.
23. Luong K.V., Nguyen L.T. The impact of thiamine treatment on generalized anxiety disorder. J Clin Med Res 2012, 4(3):153-160.
24. Obeid R., Herrmann W. Holotranscobalamin in laboratory diagnosis of cobalamin deficiency to total cobalamin and methylmalonic acid. Clin Chem Lab Med 2007, 45(12):1746-1750.
25. Ahn H.J., Min K.W., Cho Y.O. Assessment of vitamin B6 status in Korean patients with newly diagnosed type 2 diabetes. Nutr Res Pract 2001, 5(1):34-39.
26. Gorson K.C., Ropper A.H. Additional causes for distal sensory polyneuropathy in diabetic patients. J Neurol Neurosurg Psychiatry 2006, 77(3):354-358.
27. Morris M.S., Picciano M.F., Jacques P.F., Selhub J. Plasma pyridoxal 5'-phosphate in the US population: the National Health and Nutrition Examination Survey, 2003-2004. Am J Clin Nutr 2008, 87(5):1446-1454.
28. Hansen C.M., Leklem J.E., Miller L.T. Vitamin B-6 status of women with a constant intake of vitamin B-6 changes with three levels of dietary protein. J Nutr 1996, 126(7):1891-1901.
29. Bates C.J., Pentieva K.D., Prentice A., Mansoor M.A., Flinch S. Plasma pyridoxal phosphate and pyridoxic acid and their relationship to plasma homocysteine in a representative sample of British men and women aged 65 years and over. Br J Nutr 1999, 81(3):191-201.
30. Coburn S.P., Reynolds R.D., Mahuren J.D., Schaltenbrand W.E., Wang Y., Ericson K.L., et al. Elevated plasma 4-pyridoxic acid in renal insufficiency. Am J Clin Nutr 2002, 75(1):57-64.
31. Lindner A., Bankson D.D., Stehman-Breen C., Mahuren J.D., Coburn S.P. Vitamin B6 metabolism and homocysteine in end-stage renal disease and chronic renal insufficiency. Am J Kidney Dis 2002, 39(1):134-145.
32. Friso S., Jacques P.F., Wilson P.W., Rosenberg I.H., Selhub J. Low circulating vitamin B(6) is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. Circulation 2001, 103(23):2788-2791.
33. Sakakeeney L., Roubenoff R., Obin M., Fontes J.D., Benjamin E.J., Bujanover Y., et al. Plasma pyridoxal-5-phosphate is inversely associated with systemic markers of inflammation in a population of U.S. adults. J Nutr 2012, 142(7):1280-1285.
34. Cuskelly G.J., Stacpoole P.W., Williamson J., Baumgartner T.G., Gregory J.F. Deficiencies of folate and vitamin B(6) exert distinct effects on homocysteine, serine, and methionine kinetics. Am J Physiol Endocrinol Metab 2001, 281(6):E1182-E1190.
35. Lim A.K., Tesch G.H. Inflammation in diabetic nephropathy. Mediators Inflamm 2012, 2012:146154.
36. Wada J., Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond) 2013, 124(3):139-152.
37. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342(12):836-843.
38. Friedman A.N., Hunsicker L.G., Selhub J., Bostom A.G. Clinical and nutritional correlates of C-reactive protein in type 2 diabetic nephropathy. Atherosclerosis 2004, 172(1):121-125.
39. Paul L., Ueland P.M., Selhub J. Mechanistic perspective on the relationship between pyridoxal 5'-phosphate and inflammation. Nutr Rev 2013, 71(4):239-244.
40. Humphrey L.L., Fu R., Rogers K., Freeman M., Helfand M. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin Proc 2008, 83(11):1203-1212.
41. Papatheodorou L., Weiss N. Vascular oxidant stress and inflammation in hyperhomocysteinemia. Antioxid Redox Signal 2007, 9(11):1941-1958.
42. Selhub J., Jacques P.F., Wilson P.W., Rush D., Rosenberg I.H. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993, 270(22):2693-2698.
43. Atamer A., Kocyigit Y., Ecder S.A., Selek S., Ilhan N., Ecder T., et al. Effects of oxidative stress on antioxidant enzyme activities, homocysteine and lipoproteins in chronic kidney disease. J Nephrol 2008, 21(6):924-930.
44. Herrmann W., Schorr H., Obeid R., Makowski J., Fowler B., Kuhlmann M.K. Disturbed homocysteine and methionine cycle intermediates S-adenosylhomocysteine and S-adenosylmethionine are related to degree of renal insufficiency in type 2 diabetes. Clin Chem 2005, 51(5):891-897.
45. Li J., Shi M., Zhang H., Yan L., Xie M., Zhuang L., et al. Relation of homocysteine to early nephropathy in patients with type 2 diabetes. Clin Nephrol 2012, 77(4):305-310.
46. de Bree A., van der Put N.M., Mennen L.I., Verschuren W.M., Blom H.J., Galan P., et al. Prevalence of hyperhomocysteinemia, unfavorable cholesterol profile and hypertension in European populations. Eur J Clin Nutr 2005, 59(4):480-488.
47. van Guldener C. Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering?. Nephrol Dial Transplant 2006, 21(5):1161-1166.
48. Savage D.G., Lindenbaum J., Stabler S.P., Allen R.H. Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med 1994, 96(3):239-246.
49. Saito N., Kimura M., Kuchiba A., Itokawa Y. Blood thiamine levels in outpatients with diabetes mellitus. J Nutr Sci Vitaminol 1987, 33(6):421-431.
50. Maschke M., Weber J., Bonnet U., Dimitrova A., Bohrenkämper J., Sturm S., et al. Vermal atrophy of alcoholics correlate with serum thiamine levels but not with dentate iron concentrations as estimated by MRI. J Neurol 2005, 252(6):704-711.